Literature DB >> 25745068

Increased hepatic Fatty Acid uptake and esterification contribute to tetracycline-induced steatosis in mice.

You-Jin Choi1, Chae-Hyeon Lee1, Kang-Yo Lee1, Seung-Hwan Jung1, Byung-Hoon Lee2.   

Abstract

Tetracycline induces microvesicular steatosis, which has a poor long-term prognosis and a higher risk of steatohepatitis development compared with macrovesicular steatosis. Recent gene expression studies indicated that tetracycline treatment affects the expression of many genes associated with fatty acid transport and esterification. In this study, we investigated the role of fatty acid transport and esterification in tetracycline-induced steatosis. Intracellular lipid accumulation and the protein expression of fatty acid translocase (FAT or CD36) and diacylglycerol acyltransferase (DGAT) 2 were increased in both mouse liver and HepG2 cells treated with tetracycline at 50 mg/kg (intraperitoneal injection, i.p.) and 100 μM, respectively. Tetracycline increased the cellular uptake of boron-dipyrromethene-labeled C16 fatty acid, which was abolished by CD36 RNA interference. Oleate-induced cellular lipid accumulation was further enhanced by co-incubation with tetracycline. Tetracycline downregulated extracellular signal-regulated kinase (ERK) phosphorylation, which negatively regulated DGAT2 expression. U0126, a specific ERK inhibitor, also increased DGAT2 expression and cellular lipid accumulation. DGAT1 and 2 knock-down with specific small interfering (si)-RNA completely abrogated the steatogenic effect of tetracycline in HepG2 cells. Taken together, our data showed that tetracycline induces lipid accumulation by facilitating fatty acid transport and triglyceride esterification by upregulating CD36 and DGAT2, respectively.
© The Author 2015. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CD36; DGAT; drug-induced liver injury; fatty liver; tetracycline

Mesh:

Substances:

Year:  2015        PMID: 25745068     DOI: 10.1093/toxsci/kfv049

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  11 in total

Review 1.  Drug-induced steatohepatitis.

Authors:  Ajit Dash; Robert A Figler; Arun J Sanyal; Brian R Wamhoff
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-27       Impact factor: 4.481

2.  Mormodica charantia L. fruit and Genistein ameliorates type 2 diabetes in rats by preventing lipid accumulation, insulin resistance and enhancing beta cell function.

Authors:  Wusa Makena; Joseph O Hambolu; James A Timbuak; Uduak E Umana; Abdullahi I Iliya; Nathan I Dibal
Journal:  J Diabetes Metab Disord       Date:  2020-10-03

3.  Evaluation of the Potential Risk of Drugs to Induce Hepatotoxicity in Human-Relationships between Hepatic Steatosis Observed in Non-Clinical Toxicity Study and Hepatotoxicity in Humans.

Authors:  Keisuke Goda; Akio Kobayashi; Akemi Takahashi; Tadakazu Takahashi; Kosuke Saito; Keiko Maekawa; Yoshiro Saito; Shoichiro Sugai
Journal:  Int J Mol Sci       Date:  2017-04-12       Impact factor: 5.923

4.  The Protective Effect of Cynara Cardunculus Extract in Diet-Induced NAFLD: Involvement of OCTN1 and OCTN2 Transporter Subfamily.

Authors:  Francesca Oppedisano; Carolina Muscoli; Vincenzo Musolino; Cristina Carresi; Roberta Macrì; Caterina Giancotta; Francesca Bosco; Jessica Maiuolo; Federica Scarano; Sara Paone; Saverio Nucera; Maria Caterina Zito; Miriam Scicchitano; Stefano Ruga; Monica Ragusa; Ernesto Palma; Annamaria Tavernese; Rocco Mollace; Ezio Bombardelli; Vincenzo Mollace
Journal:  Nutrients       Date:  2020-05-15       Impact factor: 5.717

5.  A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease.

Authors:  Danae Stella Zareifi; Odysseas Chaliotis; Nafsika Chala; Nikos Meimetis; Maria Sofotasiou; Konstantinos Zeakis; Eirini Pantiora; Antonis Vezakis; George K Matsopoulos; Georgios Fragulidis; Leonidas G Alexopoulos
Journal:  iScience       Date:  2022-02-09

6.  Early detection of metabolic changes in drug-induced steatosis using metabolomics approaches.

Authors:  Helena Y Yong; Gerald Larrouy-Maumus; Mire Zloh; Rosemary Smyth; Rayan Ataya; Christopher M Benton; Michael R Munday
Journal:  RSC Adv       Date:  2020-11-11       Impact factor: 4.036

7.  High-salt intake negatively regulates fat deposition in mouse.

Authors:  Huanxian Cui; Shuyan Yang; Maiqing Zheng; Ranran Liu; Guiping Zhao; Jie Wen
Journal:  Sci Rep       Date:  2017-05-17       Impact factor: 4.379

Review 8.  Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update.

Authors:  Laura Giuseppina Di Pasqua; Marta Cagna; Clarissa Berardo; Mariapia Vairetti; Andrea Ferrigno
Journal:  Biomedicines       Date:  2022-01-17

Review 9.  Mitochondria as the Target of Hepatotoxicity and Drug-Induced Liver Injury: Molecular Mechanisms and Detection Methods.

Authors:  Milos Mihajlovic; Mathieu Vinken
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

10.  Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity.

Authors:  Julien Allard; Simon Bucher; Julie Massart; Pierre-Jean Ferron; Dounia Le Guillou; Roxane Loyant; Yoann Daniel; Youenn Launay; Nelly Buron; Karima Begriche; Annie Borgne-Sanchez; Bernard Fromenty
Journal:  Cell Biol Toxicol       Date:  2020-06-14       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.